Prof Jack Cuzick speaks with ecancer at SABCS 2017 about predicting late breast cancer recurrence with screening assays.
He describes how gene panels, such as the one discussed by Dr Jonathan Lancaster here, came to be following ATAC and TransATAC trials, and have incorporated a wider array of gene signatures which may indicate likelihood of relapse.
Prof Cuzick goes on to consider the future of screening in cancer prevention strategies patient survival.
